Table 5.
Observed and relative survival ratios using the Ederer II method, and adjusted estimated relative excess hazard ratios (RER) from the relative survival model using Poisson regression for postmenopausal women diagnosed with endometrial cancer in Sweden during 1993–1995 with 5-year follow-up; in relation to menopausal hormone therapy use.
| 5 YEARS | 5-YEAR FOLLOW-UP | |||
|---|---|---|---|---|
| Use of MHT| | Observed survival | Relative survival ratio (95% CI) | Observed number of deaths | RER (95% CI)▲ |
| All 683 cases with 3179 person-years at risk for 5-year follow-up | - | - | 96 | - |
| Any form of MHT¶ | ||||
| No | 0.84 | 0.90 (0.87–0.94) | 75 | 1.00 (reference) |
| Yes | 0.89 | 0.95 (0.90–0.99) | 21 | 0.40 (0.16–0.97) |
| Any form of oestrogens¶†∞ | ||||
| No | 0.85 | 0.91 (0.87–0.94) | 76 | 1.00 (reference) |
| Yes | 0.89 | 0.95 (0.89–0.99) | 20 | 0.38 (0.15–0.99) |
| Oestrogens and Progestins¶∞‡∫Ω | ||||
| No | 0.85 | 0.91 (0.87–0.94) | 84 | 1.00 (reference) |
| Yes | 0.93 | 0.98 (0.91–1.02) | 8 | 0.17 (0.01–1.96) |
| Oestrogens with cyclic progestins¶∞∫Ω | ||||
| No | 0.85 | 0.91 (0.88–0.94) | 86 | 1.00 (reference) |
| Yes | 0.94 | 0.99 (0.92–1.04) | 5 | 0.23 (0.04–1.47) |
| Low potency vaginal oestrogens§ | ||||
| No | 0.86 | 0.92 (0.88–0.94) | 83 | 1.00 (reference) |
| Yes | 0.87 | 0.93 (0.84–0.99) | 13 | 0.95 (0.39–2.29) |
| Low potency oral oestrogens~ | ||||
| No | 0.86 | 0.91 (0.88–0.94) | 78 | 1.00 (reference) |
| Yes | 0.87 | 0.94 (0.86–0.99) | 18 | 0.76 (0.34–1.71) |
Ever use of menopausal hormone therapies are not mutually exclusive
Adjusted for age and year of diagnosis
Medium potency MHT
Ever use of oestrogens with or without progestins
Conjugated oestrogens; oestradiol; or other synthetic
Use of oestrogens and progestins, cyclic and/or continuous
Cyclic progestins: added to oestrogens for less than 16 days/cycle, mostly for 10–14 days; continuous progestins: added to oestrogens for 19 or more days per cycle, mostly daily
Progesterone-like progestins (17-hydroxy-progesterone derivatives); or testosterone-like progestins (19-nor-testosterone derivatives)
Oestriol 0.5 mg; dienoestrol 0.5 mg; oestradiol 0.25 μg. Daily applications during initial 2–3 weeks of treatment, followed by applications twice per week
1–2 mg daily